Amicus Therapeutics (NASDAQ:FOLD) Downgraded to “Hold” at StockNews.com

StockNews.com cut shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research note published on Tuesday.

Several other equities research analysts have also issued reports on the stock. Morgan Stanley decreased their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 target price on the stock. JPMorgan Chase & Co. dropped their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Amicus Therapeutics in a report on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.13.

Amicus Therapeutics Stock Down 0.6 %

NASDAQ FOLD opened at $11.90 on Tuesday. The business has a fifty day moving average price of $11.17 and a two-hundred day moving average price of $10.56. The stock has a market capitalization of $3.52 billion, a PE ratio of -24.29 and a beta of 0.69. Amicus Therapeutics has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. During the same period in the prior year, the company earned ($0.15) EPS. Amicus Therapeutics’s revenue for the quarter was up 34.0% on a year-over-year basis. Equities analysts expect that Amicus Therapeutics will post -0.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $10,382,718.34. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 22,500 shares of company stock valued at $244,875 over the last ninety days. 2.20% of the stock is owned by company insiders.

Institutional Trading of Amicus Therapeutics

A number of large investors have recently bought and sold shares of the business. Blue Trust Inc. grew its stake in Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Amicus Therapeutics during the 2nd quarter worth approximately $89,000. Sage Capital Advisors llc bought a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at $103,000. Sanctuary Advisors LLC acquired a new position in shares of Amicus Therapeutics during the 2nd quarter valued at $138,000. Finally, EntryPoint Capital LLC boosted its stake in Amicus Therapeutics by 278.8% during the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 9,729 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.